Leite Ana Luísa, Galo Elisa, Antunes Ana, Robalo Brígida, Amaral Daniela, Espada Filipa, Castro Sofia, Simões Dias Sara, Limbert Catarina
Unidade de Endocrinologia e Diabetologia Pediátrica, Centro Hospitalar de Vila Nova de Gaia/Espinho, EPE, Espinho, Portugal.
Serviço de Pediatria, Departamento de Pediatria, Hospital da criança e do Adolescente, Hospital da Luz, Lisboa, Portugal.
Front Pediatr. 2022 Mar 4;10:816635. doi: 10.3389/fped.2022.816635. eCollection 2022.
There are several concerns associated with gonadotropin-releasing hormone agonist (GnRHa) treatment for central precocious puberty (CPP), such as obesity and changes in body mass index (BMI). We aimed to investigate whether any anthropometric differences exist and if they persist over time.
We conducted an observational study of Portuguese children (both sexes) diagnosed with CPP between January 2000 and December 2017, using a digital platform, in order to analyze the influence of GnRHa treatment on BMI-SD score (BMI-SDS).
Of the 241 patients diagnosed with CPP, we assessed 92 patients (8% boys) in this study. At baseline, 39% of the patients were overweight. BMI-SDS increased with treatment for girls but then diminished 1 year after stopping GnRHa therapy ( = 0.018). BMI-SDS variation at the end of treatment was negatively correlated with BMI-SDS at baseline ( < 0.001). Boys grew taller and faster during treatment than did girls ( < 0.001), and therefore, their BMI-SDS trajectory might be different.
This study showed an increase of body weight gain during GnRHa treatment only in girls, which reversed just 1 year after stopping treatment. The overall gain in BMI-SDS with treatment is associated with baseline BMI-SDS.
促性腺激素释放激素激动剂（GnRHa）治疗中枢性性早熟（CPP）存在一些问题，如肥胖和体重指数（BMI）变化。我们旨在调查是否存在任何人体测量学差异以及这些差异是否随时间持续存在。
我们使用数字平台对2000年1月至2017年12月期间诊断为CPP的葡萄牙儿童（男女均有）进行了一项观察性研究，以分析GnRHa治疗对BMI标准差评分（BMI-SDS）的影响。
在241例诊断为CPP的患者中，我们在本研究中评估了92例患者（8%为男孩）。基线时，39%的患者超重。女孩的BMI-SDS在治疗期间升高，但在停止GnRHa治疗1年后下降（P = 0.018）。治疗结束时BMI-SDS的变化与基线时的BMI-SDS呈负相关（P < 0.001）。男孩在治疗期间比女孩长得更高更快（P < 0.001），因此，他们的BMI-SDS轨迹可能不同。
本研究表明，GnRHa治疗期间仅女孩体重增加，且在停止治疗1年后体重增加逆转。治疗期间BMI-SDS的总体增加与基线BMI-SDS相关。
